Reference · GLP-1 / incretin

Retatrutide

Triple GLP-1 / GIP / glucagon receptor agonist (Eli Lilly LY3437943). Early-phase weight-change results larger than tirzepatide.

Not medical advice. The ranges below record what people log, not what anyone should take. FDA-approved compounds have separate prescribed dosing on-label.
Molecular weight
4,731.5 Da
Half-life
~6 days
Cadence people log
weekly SC
Range people log
1–12 mg / wk
Class
GLP-1 / incretin
Regulatory status
Investigational

Investigational. Phase 3 trials ongoing; not FDA-approved at the time of writing.

Reconstituting Retatrutide

The calculator takes vial mass, BAC water volume and your target dose, and returns the exact draw on a U-40, U-50 or U-100 insulin syringe. It does the arithmetic; it does not suggest what the dose should be.

Open the reconstitution calculator →

Others in GLP-1 / incretin

SemaglutideTirzepatide
← All compounds
Next
Track it, don't just look it up.
PepMe logs every injection, rotates your sites, and shows how your bloodwork and weight respond. Thirty days free.
See pricing
pepme
One app for the whole protocol — the math, the log, the journal, the labs.
Product
Company
pepme.health · 2026 · US, 18+not medical advice · descriptive, not prescriptive